Why Intercept Pharmaceuticals (ICPT) Stock Is Spiking In Pre-Market Trading Today

NEW YORK (TheStreet) -- Intercept Pharmaceuticals  (ICPT) shares are up 45.88% to $346 in pre-market trading on Tuesday after releasing positive data on its fatty liver drug treatment, obeticholic acid (OCA).

The new data shows OCA reduced the signs and symptoms of non-alcoholic steatohepatitis (NASH) compared to placebo. NASH is a disease of the liver that affects 2% to 5% of Americans and has no current treatment.

Intercept plans to start a phase III study of OCA in NASH next year.

Highlights from the analysis by TheStreet Ratings Team follows:

ICPT Chart ICPT data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE

More from Markets

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets

Global Oil Prices Mixed as OPEC Production Talks, China Tariffs Weigh on Markets

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Cryptocurrencies Could 'Bring the Internet to a Halt', Central Bank Agency Warns

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

Volkswagen's Audi CEO Arrested in Diesel Emissions Probe

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know